BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 25650089)

  • 21. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
    Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
    J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.
    Haladyna JN; Pastuer T; Riedel SS; Perraud AL; Bernt KM
    Exp Hematol; 2016 Jul; 44(7):596-602.e3. PubMed ID: 27033163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
    Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
    Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
    Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
    Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
    Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
    J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.
    Jenkins CE; Shevchuk OO; Giambra V; Lam SH; Carboni JM; Gottardis MM; Holzenberger M; Pollak M; Humphries RK; Weng AP
    Exp Hematol; 2012 Sep; 40(9):715-723.e6. PubMed ID: 22613471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hes1 suppresses acute myeloid leukemia development through FLT3 repression.
    Kato T; Sakata-Yanagimoto M; Nishikii H; Ueno M; Miyake Y; Yokoyama Y; Asabe Y; Kamada Y; Muto H; Obara N; Suzukawa K; Hasegawa Y; Kitabayashi I; Uchida K; Hirao A; Yagita H; Kageyama R; Chiba S
    Leukemia; 2015 Mar; 29(3):576-85. PubMed ID: 25234168
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Fu JF; Shih LY; Yen TH
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34080665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
    Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
    Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease.
    Risueño RM; Campbell CJ; Dingwall S; Levadoux-Martin M; Leber B; Xenocostas A; Bhatia M
    Blood; 2011 Jun; 117(26):7112-20. PubMed ID: 21562049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
    Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
    Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia.
    Kamezaki K; Luchsinger LL; Snoeck HW
    Exp Hematol; 2014 Mar; 42(3):192-203.e1. PubMed ID: 24269847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.
    Yang Z; Li Y; Yin F; Chan RJ
    Exp Hematol; 2008 Oct; 36(10):1285-96. PubMed ID: 18640765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
    Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
    Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absence of the Shb gene in mixed-lineage leukemia MLL-AF9 cells increases latency in mice despite higher proliferation rates in vitro.
    Jamalpour M; Bergquist E; Welsh M
    Exp Cell Res; 2020 Dec; 397(2):112368. PubMed ID: 33220260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes.
    Fleischmann KK; Pagel P; Schmid I; Roscher AA
    Mol Cancer; 2014 Feb; 13():27. PubMed ID: 24517546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.
    Muntean AG; Chen W; Jones M; Granowicz EM; Maillard I; Hess JL
    Blood; 2013 Sep; 122(11):1914-22. PubMed ID: 23900238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase separation of SHP2E76K promotes malignant transformation of mesenchymal stem cells by activating mitochondrial complexes.
    Kan C; Tan Z; Liu L; Liu B; Zhan L; Zhu J; Li X; Lin K; Liu J; Liu Y; Yang F; Wong M; Wang S; Zheng H
    JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38451719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.